Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artelo BiosciencesARTLW 32 3-Year EBITDA Growth Rate is 17.60% as of Jun. 2026, which is 23% below its 10-year median of 22.85. GuruFocus rates ARTLW with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Artelo Biosciences ranks better than 53.24% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 28.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Artelo Biosciences was 43.00% per year. The lowest was -115.80% per year. And the median was 22.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Artelo Biosciences 3-Year EBITDA Growth Rate Related Terms
ARTLW vs PPCB, CLDI, GNPX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Artelo Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.60% mean?
Artelo Biosciences (ARTLW) has a 3-Year EBITDA Growth Rate of 17.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Artelo Biosciences and its competitors. This is 23% below median its historical median of 22.85. According to the industry distribution chart, Artelo Biosciences ranks #527 out of 1127 companies in the Biotechnology industry, placing it in the top 46.8%.
Is Artelo Biosciences' 3-Year EBITDA Growth Rate too high?
Artelo Biosciences' current 3-Year EBITDA Growth Rate of 17.60% is 23% below median its 10-year median of 22.85. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Artelo Biosciences' value of 17.60% is 20.5% above this industry median. Based on the distribution chart, Artelo Biosciences ranks #527 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Artelo Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' 3-Year EBITDA Growth Rate compare to PPCB and CLDI?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #527 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Artelo Biosciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Artelo Biosciences' value of 17.60% is 20.5% above this benchmark. While the company's 10-year median is 22.85 vs. the industry median of 14.60, Artelo Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artelo Biosciences's current 3-Year EBITDA Growth Rate of 17.60% is 20.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Artelo Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current 3-Year EBITDA Growth Rate is 17.60%, which is 23% below median its own 10-year median of 22.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTLW) has a current 3-Year EBITDA Growth Rate of 17.60%. The current 3-Year EBITDA Growth Rate is 17.60%, which is 23% below median its 10-year median of 22.85 and 20.5% above the Biotechnology industry median of 14.60. Artelo Biosciences' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Artelo Biosciences (ARTLW), the current 3-Year EBITDA Growth Rate is 17.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
32GF Score
Get the complete analysis for ARTLW
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTLW has been successfully added to your 
